How does the TRS 2°P score relate to real-world patients?

Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):72-74. doi: 10.1093/ehjcvp/pvy004.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atherosclerosis* / blood
  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / epidemiology
  • Female
  • Global Health
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypolipidemic Agents / therapeutic use*
  • Male
  • Middle Aged
  • Morbidity / trends
  • Survival Rate / trends

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents